GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Warby Parker Inc (NYSE:WRBY) » Definitions » EBIT

Warby Parker (Warby Parker) EBIT : $-72.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Warby Parker EBIT?

Warby Parker's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-21.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-72.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Warby Parker's annualized ROC % for the quarter that ended in Dec. 2023 was -25.91%. Warby Parker's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -31.60%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Warby Parker's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4.92%.


Warby Parker EBIT Historical Data

The historical data trend for Warby Parker's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Warby Parker EBIT Chart

Warby Parker Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
-1.66 -55.63 -143.66 -111.20 -72.00

Warby Parker Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.71 -12.43 -18.23 -19.77 -21.57

Competitive Comparison of Warby Parker's EBIT

For the Medical Instruments & Supplies subindustry, Warby Parker's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Warby Parker's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Warby Parker's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Warby Parker's EV-to-EBIT falls into.



Warby Parker EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-72.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Warby Parker  (NYSE:WRBY) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Warby Parker's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-86.276 * ( 1 - 0.55% )/( (322.36 + 340.007)/ 2 )
=-85.801482/331.1835
=-25.91 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=574.879 - 78.847 - ( 215.965 - max(0, 121.81 - 295.482+215.965))
=322.36

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=580.312 - 68.776 - ( 216.894 - max(0, 127.09 - 298.619+216.894))
=340.007

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Warby Parker's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-86.276/( ( (271.468 + max(-19.207, 0)) + (274.637 + max(-21.079, 0)) )/ 2 )
=-86.276/( ( 271.468 + 274.637 )/ 2 )
=-86.276/273.0525
=-31.60 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.721 + 63.617 + 15.179) - (78.847 + 17.623 + 2.254)
=-19.207

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.779 + 62.234 + 17.712) - (68.776 + 31.617 + 2.411)
=-21.079

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Warby Parker's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-71.996/1464.139
=-4.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Warby Parker EBIT Related Terms

Thank you for viewing the detailed overview of Warby Parker's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Warby Parker (Warby Parker) Business Description

Traded in Other Exchanges
N/A
Address
233 Spring Street, 6th Floor East, New York, NY, USA, 10013
Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts to eye exams and vision tests. Brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company primarily derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
Executives
Steven Clive Miller officer: Chief Financial Officer C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
David Abraham Gilboa director, officer: Co-Chief Executive Officer C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Neil Harris Blumenthal director, officer: Co-Chief Executive Officer C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Durable Capital Partners Lp 10 percent owner 4747 BETHESDA AVENUE, SUITE #1002, BETHESDA MD 20814
Teresa Briggs director 2225 LAWSON LANE, SANTA CLARA CA 95054
Ronald A Williams director
Jeffrey Jacob Raider director C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Andrew Hunt director C/O ELEPHANT PARTNERS, 11 NEWBURY STREET, 5TH FLOOR, BOSTON MA 02116
D1 Capital Partners L.p. 10 percent owner 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Joel E Cutler director, 10 percent owner C/O GENERAL CATALYST PARTNERS, 20 UNIVERSITY ROAD, SUITE 450, CAMBRIDGE MA 02138
Youngme E Moon director 75 NETWORK DRIVE, BURLINGTON MA 01803
Daniel S. Sundheim 10 percent owner C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
General Catalyst Group V Lp 10 percent owner c/o General Catalyst Group Management LL, 20 University Road Ste 450, Cambridge MA 02138
Gabrielle Sulzberger director 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017
General Catalyst Group Management Holdings, L.p. 10 percent owner 20 UNIVERSITY ROAD, 4TH FLOOR, CAMBRIDGE MA 02138